Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
June 01, 2010 (Vol. 30, No. 11)

Changes Looming in Hepatitis C Arena

HCV Treatment Paradigms in Later Stages of Development Could Significantly Alter Landscape

  • Click Image To Enlarge +
    Hepatitis C might be amenable to treatment in the same manner as most cases of AIDS, i.e., with a therapeutic cocktail.

    The treatment of chronic hepatitis C virus (HCV) infection is on the verge of a major transformation. New drugs in the late stages of development have the potential to increase cure rates, shorten the length of therapy, and entice significant numbers of new patients to seek treatment. It is not surprising then that firms are scrambling to be among the first to get to market with these new drugs and capture a piece of the HCV treatment pie.

    The stakes are high—these new therapies have the opportunity to grow the annual market from about $2–3 billion at present to $5–10 billion (or more) in the next 10 years. The race includes Merck, Roche, Bristol-Myers Squibb, and Abbott Laboratories, as well as spirited biotech companies like Vertex Pharmaceuticals, Pharmasset, InterMune, and Idenix Pharmaceuticals.

    HCV infection, often referred to as a silent killer, is estimated to affect 170 million people worldwide and three million people in the U.S. Many of these patients are undiagnosed and others can be asymptomatic for years. If left untreated, however, HCV can lead to cirrhosis and liver cancer.

    Many HCV patients contracted the disease from blood transfusions before the blood supply was screened for HCV in 1992. Others contracted the disease from IV drug needles, tattoo needles, and unprotected sex.

    The current standard of care (SOC) is weekly injectable pegylated interferon (IFN) and twice-daily oral ribavirin (RBV). RBV helps boost the body’s immune response and while RBV’s mechanism of action is not well understood (it has little to no effect on its own), it improves the effectiveness of IFN when dosed in tandem. However, this SOC is not a panacea.

    In genotype 1 patients (the predominant genotype in the U.S.), the treatment regimen lasts 48 weeks and leads to a cure in only 40–50% of patients. In addition to suboptimal cure rates, the SOC has an array of side effects including flu-like symptoms, depression, fatigue, and anxiety. Convincing patients to start and adhere to therapy can be difficult; as a result, only a small fraction of diagnosed patients are treated each year.

    Treatment-failure patients have fewer options. For the more than 50% of patients who were treated with the standard of care and failed to achieve a cure (due to poor response, intolerance to SOC, lack of adherence, or disease relapse), alternatives are almost nonexistent. Retreatment with SOC has a poor success rate (less than 20%). As more patients are treated each year, the population of treatment-failure patients is large and growing.

    The current treatment-failure population is estimated to be between 300,000 and 500,000 in the U.S. alone. These individuals may be among the first patients to seek therapy when new drugs are approved, and the first drugs to market will likely capture the revenue associated with treating this reservoir of patients.

    Direct acting antiviral drugs are some of the oral compounds being developed to improve the treatment of HCV. The two most advanced drugs are HCV protease inhibitors—telaprevir from Vertex and boceprevir from Merck. Both products are in Phase III trials with results expected this year; potential approval and launch could occur sometime in 2011.

Related content